Chondrosarcoma epidemiology and demographics

Revision as of 14:47, 25 March 2019 by Farima Kahe (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Chondrosarcoma Microchapters


Patient Information


Historical Perspective




Differentiating Chondrosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray

Echocardiography and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chondrosarcoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Chondrosarcoma epidemiology and demographics

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chondrosarcoma epidemiology and demographics

CDC on Chondrosarcoma epidemiology and demographics

Chondrosarcoma epidemiology and demographics in the news

Blogs on Chondrosarcoma epidemiology and demographics

Directions to Hospitals Treating Chondrosarcoma

Risk calculators and risk factors for Chondrosarcoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Rohan A. Bhimani, M.B.B.S., D.N.B., M.Ch.[2]


Chondrosarcoma is the second most common malignant primary tumor of bone. It is most frequently diagnosed in patients in their 4th and 5th decades of life. Men are slightly more affected by chondrosarcoma than women. There is no racial predilection to chondrosarcoma.

Epidemiology and Demographics


  • Chondrosarcoma is the second most common primary bone sarcoma.[1]
  • The incidence of chondrosarcoam is approximately 1 per 100,000 individuals worldwide.[2]


  • Chondrosarcoma is most frequently diagnosed in patients in their 4th and 5th decades of life.[3]
  • The average age at presentation is 51 years.


  • There is no racial predilection to chondrosarcoma.[2]


  • Chondrosarcoma affects men and women almost equally with slight male predominance.[4]
  • Exception to this is the clear cell sub-type which has significant male preponderance.
  • The male to female ratio is almost 1:1 except for clear cell chondrosarcoma it is 2.4:1.


  1. Peabody, Terrance (2014). Orthopaedic oncology : primary and metastatic tumors of the skeletal system. Cham: Springer. ISBN 9783319073224.
  2. 2.0 2.1 Lex JR, Evans S, Stevenson JD, Parry M, Jeys LM, Grimer RJ (2018). "Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment". Clin Sarcoma Res. 8: 23. doi:10.1186/s13569-018-0110-1. PMC 6293503. PMID 30559960.
  3. Unni KK (2001). "Cartilaginous lesions of bone". J Orthop Sci. 6 (5): 457–72. PMID 11845358.
  4. Weber KL, Raymond AK (2002). "Low-grade/dedifferentiated/high-grade chondrosarcoma: a case of histological and biological progression". Iowa Orthop J. 22: 75–80. PMC 1888368. PMID 12180616.

Template:WH Template:WS